Christopher-Paul Milne, DVM, MPH, JD

Chris Milne

Director of Research




.(JavaScript must be enabled to view this email address)

Research Focus

Identifying and evaluating problems and solutions affecting innovation efficiency and the globalization of R&D; tracking the progress of incentive programs for special patient populations (pediatric and orphan diseases) and neglected diseases of the developing world; assessing the impact of emerging regulatory and reimbursement trends, such as risk evaluation and mitigation strategies (REMS) in the US and Europe’s risk management plan (EU-RMP) program, comparative effectiveness, and risk-sharing arrangements; and, updating developments in  new science and policy initiatives, such as personalized medicine, FDA’s Regulatory Science initiative, the EU’s Innovative Medicines Initiative, and Translational Medicine.

Select Publications

  1. Milne C-P, Kaitin KI. Impact of the New U.S. Health Care Reform Legislation on the Pharmaceutical Industry: Who are the Real Winners? Clin Pharm Ther 2010 Nov;88(5):589-592.
  2. Zycher B, DiMasi JA, Milne C-P. Private sector contributions to pharmaceutical science: thirty five summary case histories. Am J Ther 2010 Jan-Feb;17(1):101-20.
  3. Milne C-P. Can translational medicine bring us out of the R&D wilderness? Personalized Med 2009;6(5):543-553.
  4. Milne C-P, Tait J. Evolution along the government-governance continuum: FDA’s Orphan Products and Fast Track programs as exemplars of “what works” for innovation and regulation. Food & Drug Law J 2009;64(4):733-753.
  5. Milne C-P, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther Nov 2008;30(11):2133-2145.
  6. Faden L, Milne C-P. Pharmacovigilance activities in the United States, European Union, and Japan: harmonic convergence or convergent evolution? Food & Drug Law J 2008:63(3):683-700.
  7. Milne C-P. Fixing the paradigm for biopharmacutical R&D: Where to start? Internat’l J Biotech 2008;10(5):404-415.
  8. Milne C-P. Paediatric assessment: an essential part of standard drug development. Internat’l J Pharm Med 2006;20(5):297-301.
  9. Milne C-P. US and European regulatory initiatives to improve R&D performance. Expert Opin Drug Discov 2006; 1(1):11-14.
  10. Milne C-P. Status critical at the FDA or a case of the Socratic problem? Johns Hopkins Advanced Studies in Medicine 2005;5(10):514-17.
  11. Milne C-P. Racing the globalization of infectious diseases: lessons from the tortoise and the hare.  N Engl J Internat’l & Comparative Law 2004 Fall;11(1):1-36.